Recruiting historically under-represented individuals into Project ECHO Diabetes: using barrier analysis to understand disparities in clinical research in the USA.
Clinical Trial
DIABETES & ENDOCRINOLOGY
Health Equity
Patient Participation
STATISTICS & RESEARCH METHODS
Journal
BMJ open
ISSN: 2044-6055
Titre abrégé: BMJ Open
Pays: England
ID NLM: 101552874
Informations de publication
Date de publication:
30 08 2023
30 08 2023
Historique:
medline:
1
9
2023
pubmed:
31
8
2023
entrez:
30
8
2023
Statut:
epublish
Résumé
Individuals under-recruited in diabetes research studies include those not seen at endocrinology centres and those from rural, low socioeconomic and/or under-represented racial/ethnic groups. The purpose of this descriptive analysis is to detail recruitment and retention efforts of Project ECHO Diabetes clinical sites affiliated with Stanford University and University of Florida. Prospective collection of participant engagement and qualitative analysis of barriers and facilitators of research engagement within Project ECHO Diabetes, a virtual tele-education programme for healthcare providers in the management of individuals with insulin-requiring diabetes. Data were collected at the patient level, provider level and clinic level between 1 May 2021 and 31 July 2022. Participants and study personnel were recruited from 33 Project ECHO Diabetes sites in California and Florida. We report study completion rates for participants recruited into 33 Project ECHO Diabetes sites. Using barrier analysis, a methodology designed for the real-time assessment of interventions and system processes to identify barriers and facilitators, study personnel identified significant barriers to recruitment and retention and mapped them to actionable solutions. In total, 872 participants (California n=495, Florida n=377) were recruited with differing recruitment rates by site (California=52.7%, Florida=21.5%). Barrier analysis identified lack of trust, unreliable contact information, communication issues and institutional review board (IRB) requirements as key recruitment barriers. Culturally congruent staff, community health centre (CHC) support, adequate funding and consent process flexibility were solutions to address recruitment challenges. Barriers to retention were inconsistent postal access, haemoglobin A1c kit collection challenges, COVID-19 pandemic and broadband/connectivity issues. Additional funding supporting research staff and analogue communication methods were identified as solutions address barriers to retention. Funded partnerships with CHCs, trusted by their local communities, were key in our recruitment and retention strategies. IRB consent process flexibility reduced barriers to recruitment. Recruiting historically under-represented populations is feasible with funding aimed to address structural barriers to research participation.
Identifiants
pubmed: 37648378
pii: bmjopen-2023-072546
doi: 10.1136/bmjopen-2023-072546
pmc: PMC10471869
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
e072546Subventions
Organisme : NIDDK NIH HHS
ID : K23 DK131342
Pays : United States
Organisme : NIDDK NIH HHS
ID : P30 DK116074
Pays : United States
Informations de copyright
© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: RL has consulted for Abbott Diabetes Care, Biolinq, Capillary Biomedical, Deep Valley Labs, Morgan Stanley, Glooko, and Tidepool. DMM has received research support from the National Institutes of Health, JDRF, NSF and the Helmsley Charitable Trust; and his institution has received research support from Medtronic, Dexcom, Insulet, Bigfoot Biomedical, Tandem and Roche. He has consulted for Abbott, the Helmsley Charitable Trust, Sanofi, Novo Nordisk, Eli Lilly, and Insulet, and is supported by grant number P30DK116074. MJH has reserved research support from the NIH, JDRF and the Helmsley Charitable Trust and has been a consultant for Mannkind and Sanofi. Theremaining authors have no potential conflicts of interest relevant to this article.
Références
Diabetes Spectr. 2022 Summer;35(3):295-303
pubmed: 36082018
Circulation. 2020 Mar 10;141(10):e615-e644
pubmed: 32078375
Diabetology (Basel). 2022 Sep;3(3):494-501
pubmed: 37163187
J Am Heart Assoc. 2020 Apr 7;9(7):e015539
pubmed: 32208828
Diabetes Care. 2021 Jul;44(7):1480-1490
pubmed: 34001535
Am J Prev Cardiol. 2021 Aug 20;8:100250
pubmed: 34485967
Clin Diabetes. 2020 Apr;38(2):159-165
pubmed: 32327888
Contemp Clin Trials. 2015 Mar;41:39-44
pubmed: 25542611
Diabetes Educ. 2013 Mar-Apr;39(2):222-30
pubmed: 23439692
J Contin Educ Health Prof. 2016 Summer;36 Suppl 1:S48-9
pubmed: 27584072
J Clin Endocrinol Metab. 2020 Sep 1;105(9):
pubmed: 32676640
J Pain Symptom Manage. 2022 Jan;63(1):151-159
pubmed: 34161811
J Clin Transl Sci. 2023 Jan 23;7(1):e47
pubmed: 36845305
Acad Med. 2007 Feb;82(2):154-60
pubmed: 17264693
Curr Probl Cardiol. 2019 May;44(5):148-172
pubmed: 30545650
Lancet Gastroenterol Hepatol. 2021 Aug;6(8):605-607
pubmed: 34246352
BMJ Open Diabetes Res Care. 2021 Jul;9(1):
pubmed: 34244218
Circulation. 2019 Nov 19;140(21):1690-1692
pubmed: 31738602
Diabetes Technol Ther. 2021 Aug;23(8):537-545
pubmed: 33826420
J Gen Intern Med. 2019 Dec;34(12):2842-2857
pubmed: 31485970
J Pediatr Psychol. 2021 Jul 20;46(6):611-620
pubmed: 33570144
Acad Med. 2016 Oct;91(10):1439-1461
pubmed: 27489018
Diabetes Care. 2021 Jun;44(6):e121-e123
pubmed: 34016613
Clin Trials. 2023 Jun 17;:17407745231175919
pubmed: 37329282
J Biomed Inform. 2019 Jul;95:103208
pubmed: 31078660
Diabetologia. 2022 Sep;65(9):1461-1472
pubmed: 35705796
Contemp Clin Trials. 2015 Nov;45(Pt A):34-40
pubmed: 26188163
Diabetes Care. 2020 Nov 2;:
pubmed: 33139407
Biometrics. 2005 Mar;61(1):295-304
pubmed: 15737106
Am J Public Health. 2014 Feb;104(2):e16-31
pubmed: 24328648